What Has Changed For Alnylam Pharmaceuticals Since Its 52% Fall

If you had backed the more optimistic analyst case on Alnylam Pharmaceuticals a year ago, the result has been painful. Investors who held Alnylam Pharmaceuticals over the past year are down 51.9%, including dividends. That outcome clashes with earlier projections built on rapid AMVUTTRA uptake, expanding RNAi indications, and higher future profit margins. Which of those specific assumptions about market share, pricing resilience, or pipeline execution failed to match what actually unfolded over the period?

The move put Alnylam Pharmaceuticals in the middle of this trade. Scan 33 healthcare AI stocks for other companies exposed to it.

The Argument You Would Have Been Weighing Up On Alnylam Pharmaceuticals

The shares cost US$481 at the start of the period, and anyone looking at Alnylam Pharmaceuticals then had to choose between two very different but plausible stories.

The bullish narrative saw a Fair Value of US$559, effectively a price implied by assumptions of rapid AMVUTTRA uptake and majority market share arriving sooner. That view leaned on RNAi advances, high-prevalence indications and an eventual lift in profit margins from a loss of 13.0% to 46.9%.

The more cautious camp still expected progress but put Fair Value at US$447, again as an output of its own model rather than a quoted fact. This angle leaned on worldwide RNAi expansion and 41.8% assumed annual revenue growth, while flagging margin compression, regulatory risk and ongoing dependence on the TTR franchise.

What The Results Changed For The Alnylam Pharmaceuticals Debate

Alnylam Pharmaceuticals reported Q2 2026 revenue of US$1,290.948 million and net income of US$164.494 million, with net margin moving from a loss of 9.3% in Q2 2025 to a 12.7% profit. That shift toward profitability supports the more optimistic view on margins, while the July 2026 cut to TTR sales guidance and related legal investigations aligns with the more cautious view on concentration and pricing pressure. Overall, the evidence pointed in both directions.

The key lesson is simple. When a story hinges on rapid uptake and richer margins, it can help to track guidance for the lead franchise and the reported net margin side by side, then assess whether the price paid assumes that both continue to improve.

What You Would Be Paying For In Alnylam Pharmaceuticals Today

Alnylam Pharmaceuticals now trades at US$232, with this Narrative’s Fair Value sitting above that level. The argument leans on RNAi breadth and the ATTR franchise as the engine for future cardiovascular and metabolic opportunities rather than a single TTR line.

A buyer today would need to believe that pivotal RNAi programs such as zilebesiran reach large indications at scale while AMVUTTRA access and physician usage remain broadly intact.

"The broad RNAi portfolio at Alnylam Pharmaceuticals, with more than 25 programs across rare, specialty and prevalent conditions and multiple pivotal studies underway, creates repeated opportunities for new approvals that could add incremental revenue streams and help spread fixed R&D and SG&A over a larger sales base, which may support earnings."

The price and this Narrative do not agree. → Uncover what this Narrative says Alnylam Pharmaceuticals is actually worth

Looking Beyond Alnylam’s Specialty Focus

Alnylam Pharmaceuticals lives in rare disorders. Your attention may drift toward broader cardiometabolic problems next.

Weight, blood sugar and related conditions pressure healthcare systems in a different way. Those issues call for drugs that patients can use at scale.

One large player has built its entire engine around injections for diabetes and obesity. It is also pushing a potential next generation treatment that targets several signals at once.

The same group is working on a pill version of this drug class. Easier delivery could pull in people who avoid injections and shift how demand develops over time.

It is written up in full, assumptions and all. → Explore the Narrative that puts this company 18% above its price

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com